+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine



Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine



Journal of Immunology 185(12): 7262-7273



The influence of preexisting immunity to viral vectors is a major issue for the development of viral-vectored vaccines. In this study, we investigate the effect of preexisting vaccinia virus immunity on the immunogenicity and efficacy of a DNA/modified vaccinia Ankara (MVA) SIV vaccine in rhesus macaques using a pathogenic intrarectal SIV251 challenge. Preexisting immunity decreased SIV-specific CD8 and CD4 T cell responses but preserved the SIV-specific humoral immunity. In addition, preexisting immunity did not diminish the control of an SIV challenge mediated by the DNA/MVA vaccine. The peak and set point viremia was 150- and 17-fold lower, respectively, in preimmune animals compared with those of control animals. The peak and set point viremia correlated directly with colorectal virus at 2 wk postchallenge suggesting that early control of virus replication at the site of viral challenge was critical for viral control. Factors that correlated with early colorectal viral control included 1) the presence of anti-SIV IgA in rectal secretions, 2) high-avidity binding Ab for the native form of Env, and 3) low magnitude of vaccine-elicited SIV-specific CD4 T cells displaying the CCR5 viral coreceptor. The frequency of SIV-specific CD8 T cells in blood and colorectal tissue at 2 wk postchallenge did not correlate with early colorectal viral control. These results suggest that preexisting vaccinia virus immunity may not limit the potential of recombinant MVA vaccines to elicit humoral immunity and highlight the importance of immunodeficiency virus vaccines achieving early control at the mucosal sites of challenge.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055115013

Download citation: RISBibTeXText

PMID: 21076059

DOI: 10.4049/jimmunol.1000751


Related references

Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice. Infection and Immunity 77(9): 3958-3968, 2009

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. Journal of Virology 88(17): 9579-9589, 2014

Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Vaccine 2019, 2019

Renal transplantation and viral infections. IV. A survey of herpes simplex virus excretion in relation to cellular specific immunity and humoral immunity among renal transplant recipients. Biomedicine / 28(6): 328-332, 1978

Renal transplantation and viral infections part 4 a survey of herpes simplex virus excretion in relation to cellular specific immunity and humoral immunity among renal transplant recipients. Biomedicine 28(6): 328-332, 1978

Two types of immunity in experimental typhoid; cellular immunity and humoral immunity. Keio J Med 14(2): 45-60, 1965

Semliki forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity. Vaccine 23(33): 4189-4194, 2005

Cellular and humoral immunity against vaccinia virus infection of mice. Journal of Immunology 172(10): 6265-6271, 2004

Cellular and humoral immunity parameters and non-specific immunity condition in elderly patients with complicated hernias of the anterior abdominal wall. Uzbekiston Tibbiet Zhurnali (1): 79-80, 2001

Influence of promoter, gene copy number, and preexisting immunity on humoral and cellular responses to a vectored antigen delivered by a Salmonella enterica vaccine. Clinical and Vaccine Immunology 16(1): 78-87, 2008

Course of the vaccinal process induced by the vaccinia virus in cyclophosphane-suppressed cellular and humoral immunity. Voprosy Virusologii 1983(3): 322-325, 1983

Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge. Molecular Therapy 14(3): 432-441, 2006

Recombinant vaccinia virus expressing middle pres 2 s protein of the hepatitis b virus envelope induction of humoral and cellular immunity as a result of the immunization of laboratory animals. Doklady Akademii Nauk SSSR 314(2): 488-491, 1990

Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. Journal of Infectious Diseases 143(4): 585-589, 1981

Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity. Virus Genes 27(3): 269-282, 2003